U.S., Nov. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07239947) titled 'A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD)' on Sept. 28.
Brief Summary: This is a Phase 1, randomized, blinded, placebo controlled, single ascending dose (SAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis (AD).
Study Start Date: Aug. 09
Study Type: INTERVENTIONAL
Condition:
Atopic Dermatitis
Intervention:
DRUG: BBT001
BBT001 will be administered
DRUG: Placebo
Placebo will be administered
Recruitment Status: RECRUITING
Sponsor: Bambusa Therapeutics
Published by HT Digital Content Services wit...